Effect of chloroquine on the bioavailability of ciprofloxacin in humans

American Journal of Therapeutics

Volumn 13, Issue 5, 2006, Pages 432-435

  Ilo, C E ^a   Ilondu, N A ^a   Okwoli, N ^b   Brown, S A ^c   Elo Ilo, J C ^a   Agbasi, P U ^d   Orisakwe, O E ^a,d  

^a NNAMDI AZIKIWE UNIVERSITY   (Nigeria)

^b ABIA STATE UNIVERSITY   (Nigeria)

^c UNIVERSITY OF UYO   (Nigeria)

^d IMO STATE UNIVERSITY   (Nigeria)

Author keywords

Chloroquine bioavailability; Ciprofloxacin; Malaria; Pharmacokinetics

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGAR GEL DIFFUSION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MEGADOSE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PARASITEMIA; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; ANTIMALARIALS; AREA UNDER CURVE; BACTERIA; BIOLOGICAL ASSAY; CHLOROQUINE; CIPROFLOXACIN; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS;

EID: 33748950109     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000178911.18614.e3     Document Type: Article

References (21)

1. Watkins WM. Pharmacology and pharmacokinetics of new antimalarials. Gesnerus. 1999;56:107-199.
2. White N. Anti-malaria drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci. 1999;354:739-749.
3. Daavis R, Markham A, Balfour JA. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs. 1996;51:1019-1074.
4. Tripathi KD, Sharma AK, Valecha N, et al. In vitro activity of fluoroquinolone against chloroquine sensitive Plasmodium falciparum. Indian J Malarial. 1993;30:67-73.
5. Watt G, Shanks GD, Edstein MD, et al. Ciprofloxacin treatment of drug resistance falciparum malaria. J Infect Dis. 1991;164:602-604.
6. Watt G, Shanks GD, Edstein MD, et al. Ciprofloxacin treatment of drug resistance falciparum malaria. J Infect Dis. 1991;164:602-604.
7. Mahmoudi N, Cicerom L, Franetich J-F, et al. In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage plasmodium spp. Antimicrob Agents Chemother. 2003;47:2636-2639.
8. Pradines B, Rogier C, Fusai T, et al. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob Agents Chemother. 2001;45:1746-1750.
9. Biswas S. In vitro activity of azithromycin against chloroquine sensitive and chloroquine Biswas resistant Plasmodium falciparum. J Postgrad Med. 2001;47:240-243.
10. Tripathi KD, Sharma AK, Valecha N. Norfloxacin in the treatment of Vivax malaria. Med Sci Res. 1993;21:159-160.
11. Lacy C. Ciprofloxacin: drug information. Handbook Up to Date. 1978;7:4.
12. Bray PG, Ward SA. Malaria chemotherapy: resistance to quinolone containing drugs in Plasmodium falciparum. FEMS Microbiol Lett. 1993;113:1-7.
13. Garrod L, Lambert HP, O'Grady F. Antibiotic and Chemotherapy. Edinburgh and London: Churchill Livingstone, 1973. Clinical Bacteriology, 5th ed. Stokes EJ, Ridgway GL. 1980.
14. Edwards G, Winstanley PA, Ward SA. Clinical pharmacokinetics in the treatment of tropical diseases. Clin Pharmacokinet. 1994;27:150-165.
15. Stomberg A, Bjorkman A. Ciprofloxacin does not achieve radical cure of Plasmodium falciparum infection in Sierra Leone. Trans R Soc Topic Med Hyg. 1992;86:373.
16. Divo AA, Satorelli AC, Palton Q, et al. Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1988;32:1182-1186.
17. Pazzuceoni F, Barbi S, Baldassarre D, et al. Ironovotransferrin preparation does not interfere with ciprofloxacin absorption. Clin Pharmacol Ther. 1996;59:418-422.
18. Polk RE, Healy DD, Sahai J, et al. Effects of ferrous sulphate and multivitamins with zinc in absorption of ciprofloxacin in normal volunteers. Antimicrob Agent Chemother. 1989;33:1841-1844.
19. Taylor WR, Widjaja H, Richie TL, et al. chloroquine/doxycycline combination versus chloroquine alone for the treatment of Plasmodium falciparum and Plasmodium vivax malaria in Northeastern Irian Jaya, Indonesia. Am J Trop Med Hyg. 2001;64:2523-2528.
20. Phillips RE, Looareesuwan S, Karbwang J, et al. Failure of chloroquine-erythromycin andchloroquine-tetracycline combinations in the treatment of chloroquine-resistant falciparum malaria in eastern Thailand. Lancet. 1984;1:300-302.
21. Angela M, Avery HJ, Goddard ER, et al. Iron blocks the accumulation and activity of tetracyclines in bacteria. Antimicrob Agents Chemother. 2004;448:1892-1894.